Epocrates vs Lexicomp (UpToDate Lexidrug): cost, depth and which to buy

Yes. Wolters Kluwer rebranded Lexicomp as UpToDate Lexidrug, and the vendor store and university library guides now list it as "UpToDate Lexidrug (formerly Lexicomp)". It is one product line under two names, which is why a search for one turns up documentation written about the other. Confusingly, the mobile app still sells subscription packages under the older Lexicomp naming, so you can be looking at the new brand and the old package names on the same screen.

The practical consequence is that comparisons written before the rename are still about the current product, and you should not discount them as out of date on the name alone. It also means that when a colleague says their hospital "has Lexicomp", they almost certainly have Lexidrug access under a current Wolters Kluwer contract. If you are evaluating vendors, ask about Lexidrug; if you are searching for guidance, search both.

For an individual, the clearest published figure is the mobile subscription: Apple's US App Store listing for UpToDate Lexidrug shows in-app subscriptions (Lexicomp Professional Package and Lexi-COMPLETE) at $29.99, and the listing states that the subscription renews at $29.99 per month after the trial. Held for a year that is roughly $360, which is about double what Epocrates+ costs at $179.99 annually. We keep the current figures and the sourcing behind them in our breakdown of what Lexicomp and UpToDate Lexidrug actually cost.

For an organization there is no published list price at all. Lexidrug is sold to hospitals, health systems and libraries on negotiated contracts, and what you pay depends on headcount, which content sets you take and what else you already buy from the same vendor. You will see monthly dollar figures for Lexicomp quoted on software directory sites; those are not published by Wolters Kluwer and we do not repeat them, for the same reason we refuse to quote a list price for Micromedex. Ask for the quote, and ask for it next to the bundled configuration.

They are built for different depths of question. Epocrates is optimized for the thirty seconds you have in a corridor: open, search, get the dose or the interaction, close. Lexidrug is optimized for the question behind the question, the one where you need to know how a recommendation was derived, what the dosing looks like in an edge case, and what a pharmacist would flag. If you push Epocrates into that second job it runs out of detail, and if you push Lexidrug into the first it feels slow.

For most ambulatory prescribers who are paying personally, Epocrates wins on cost and speed and the free tier is genuinely usable. For pharmacists, hospitalists and anyone whose orders get verified by a pharmacy team, Lexidrug is the reference that matches the standard they will be held to. The honest answer for a lot of clinicians is that they use the free Epocrates tier daily and reach for their employer's Lexidrug license when the question gets hard. If you are weighing this against a broader evidence reference rather than another drug database, our UpToDate vs Epocrates comparison covers that trade-off.

It can, and in many health systems it does. Wolters Kluwer sells Lexidrug with integrations into major electronic health records including Epic, MEDITECH and Cerner, so clinicians reach drug content from context-specific links inside the chart rather than opening a separate app. In July 2026 Wolters Kluwer and Epic announced a combined offering that packages UpToDate Lexidrug with Medi-Span and patient education into a single integrated procurement, aimed particularly at rural hospitals, federally qualified health centers and smaller ambulatory practices that do not have the informatics staff to validate three standalone tools.

What that means for you is simple: whether you have it is a licensing question, not a product question. Before you pay for a personal subscription, log into your EHR and look for a drug reference link in the medication activity, and check your medical library, because a large number of US clinicians buy access their employer already provides. That single check saves more money than any comparison of list prices.

Lexidrug, and it is not close. Therapeutic interchange is a formulary process rather than a lookup: a P&T committee approves the substitutions, pharmacy applies them against a monograph-level understanding of equivalent dosing, and the decision has to be defensible afterward. That work needs the depth, the institutional licensing and the EHR presence Lexidrug is built and sold for. Epocrates is an individual mobile app, and it is not designed to carry a health system's formulary logic.

The practical division in a hospital is that the two do not really compete. Prescribers keep Epocrates on a phone for a fast dose or interaction check between patients, and pharmacy works from Lexidrug inside the chart when verifying and substituting orders. If you are being asked which one supports substitution at scale, the answer is the compendium your pharmacy already verifies against, and the licensing thresholds behind that decision are in our guide to institutional and group licensing.

For dentistry the calculation is different from hospital pharmacy, because the prescribing is narrower. Dental practice concentrates on antibiotics, analgesics and local anesthetics, with the recurring hard questions being interactions with what the patient already takes, antibiotic prophylaxis decisions, and dose limits in patients with hepatic or renal impairment. Epocrates covers that range well and its free registered tier already answers most of it, which is why a solo or small dental practice rarely needs a pharmacy-grade compendium. Hospital-based oral and maxillofacial surgery is the exception, and there you use whatever the health system licenses. Wolters Kluwer also sells a dental-specific edition, Lexidrug for Dentistry, with no published price; we compare it against Epocrates on the dental fields and the cost in our dental drug reference software guide.

An academic health sciences library is solving the opposite problem. It buys for depth, for coverage that supports pharmacy and clinical curricula, and for authentication that works off campus for thousands of affiliated users, which is exactly what Lexidrug is sold to do and exactly what an individual mobile app is not. Epocrates group subscriptions are tiered by license count and still behave like a collection of personal accounts, so they do not fill a reference collection role. We cover how that access actually works, and how to check what your institution already licenses, in our guide to medical library access to UpToDate, Lexidrug and Epocrates. If the comparison you are running is against the other pharmacy-grade compendium rather than against a phone app, see Lexicomp vs Micromedex.

Both tools answer the question you think to ask. Neither one watches the prescription you are about to sign and tells you, unprompted, that this patient is already on something that interacts with it, that their kidney function makes the standard dose wrong, or that a documented allergy rules out the obvious first choice. Getting that from a drug reference means knowing to run four separate lookups, and prescribing errors cluster precisely where nobody thought to look.

That is the job Prescriber.io is built for. You enter the drug or the scenario once and it checks for drug-drug interactions, flags contraindications and allergy blockers, surfaces renal and hepatic dose adjustments, and suggests guideline-based alternatives, together, with a cited source on each flag so you can confirm it. It is decision-support, not autonomous prescribing: every flag is a prompt for a licensed clinician who reviews it, verifies against official sources, and signs. Clinicians who arrived here from a search for a Lexicomp alternative are usually after exactly this, a faster path from drug detail to a decision, and the wider field is laid out in our guide to the best clinical decision support software.